Search

everythinglearnresearchcommunity

for

Search:↓

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.

Nanoxidil, a minoxidil derivative, is being discussed as a potential hair loss treatment. Users are curious about its effectiveness and side effects compared to minoxidil, with some noting it includes additional ingredients like caffeine.

A user shared a 14-month hair loss treatment update using dutasteride, minoxidil foam, a 1.5mm derma roller, and Nizoral, with noticeable hair regrowth and no side effects. The discussion highlights the effectiveness of microneedling in combination with topical treatments, with many users agreeing it significantly enhances results.

User shared a 4-month progress update on using minoxidil and 1.5 months on finasteride for hair loss. Reactions were mixed, with some expressing disbelief and others feeling inspired to start treatment.

Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.

The user experienced significant hair regrowth over four months using 1 mg finasteride, 2.5 minoxidil, and occasional ketoconazole. They reported no side effects from the treatments.

Brian Dye's theory links skeletal malocclusion type II to hair loss, suggesting it's a blood flow issue. Treatments mentioned include minoxidil, finasteride, and anti-inflammatory drugs like benaxoprofen.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

The user's progress with treating their hair loss with finasteride and minoxidil, as well as using a derma-roller infrequently and Nizoral shampoo twice a week. They discussed how helpful it was for the user to post comparison pictures with the same angle and lighting in each.

9 Month Update: Topical Fin/Min (0.3%, 6%), Weekly Microneedle 1.5mm, 40 Years Old. User shares progress pictures and discusses hair loss treatments used.

HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.

The user is using topical finasteride, minoxidil, nizoral shampoo, and microneedling for hair regrowth but hasn't seen results after 2-3 weeks. They added tretinoin to their routine and are advised to wait a few months for potential changes.

The user experienced significant hair growth using topical finasteride and minoxidil but noticed nipple changes, suggesting early gynecomastia. They plan to stop the treatment and consider blood work to check hormonal balance.

The user is experiencing positive hair regrowth results after four months of using oral finasteride (1mg daily), oral minoxidil (5mg daily), Polaris NR02 shampoo, and ketoconazole 2% shampoo. They plan to continue the regimen and consider a hair transplant in the future, with no reported side effects from the current treatment.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

Hair loss treatment with finasteride, minoxidil, microneedling, and nizoral shows impressive results after 3 years. Dermatologist recommended starting with finasteride before adding other treatments.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

A user shared their successful hair loss treatment using 1.25mg finasteride daily, 2.5mm microneedling every 1-3 weeks, zinc pyrithione shampoo, occasional scalp massages, and 40% glycolic acid on temples. They reported significant progress over 21 months.

Orient Bio is developing a PLGA formulated version of Cyclosporine A to stimulate hair growth without its immunosuppressant effects. Users discuss various treatments like Clascoterone, PP405, minoxidil, and tacrolimus, expressing hope for new developments and sharing personal experiences with these treatments.

A 24 year old man suffering from male pattern baldness who has been using minoxidil foam and Redensyl (no longer using) for four months, resulting in general thickening of the hair with some regrowth. The user is also awaiting to get a Finasteride prescription and hormone panel done.

The user began experiencing hair loss a few years ago at age 22 and is a diffuse thinner with a Norwood scale rating of 2. They have a naturally athletic build and gain muscle easily, with a hairy chest and stomach.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

A user maintains NW2 hair with 1mg finasteride, 2.5mg oral minoxidil, and 5% topical minoxidil twice daily, along with ketoconazole shampoo and derma stamping. They seek advice on more aggressive treatments to achieve NW1.